We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy

By LabMedica International staff writers
Posted on 23 Jan 2024

Understanding tumor responses to drugs becomes challenging due to the complex nature of DNA replication, a critical target for many cancer treatments. More...

All cells, including cancer ones, depend on a sophisticated system for DNA replication during cell division. Most chemotherapies aim to disrupt this replication process in rapidly multiplying tumor cells. Given the diverse genetic mutations in tumors, predicting drug resistance remains a formidable challenge. Now, scientists have developed a machine learning algorithm capable of predicting when cancer will resist chemotherapy. This model was specifically tested on cervical cancer, accurately predicting responses to cisplatin, a widely used chemotherapy drug. It efficiently identified tumors likely to resist treatment and shed light on the molecular mechanisms driving this resistance.

Developed by the University of California San Diego School of Medicine (La Jolla, CA, USA), the algorithm assesses how various genetic mutations collectively impact a tumor's response to DNA replication-inhibiting drugs. The research centered around 718 genes typically analyzed in clinical genetic testing for cancer. These genes' mutations formed the basis for the machine learning model, trained using publicly available drug response data. This process led to the identification of 41 molecular complexes — clusters of interacting proteins — where genetic alterations affect drug effectiveness. The model's efficacy was particularly demonstrated in cervical cancer, where approximately 35% of tumors show resistance to treatment.

The algorithm successfully distinguished between tumors that were likely to respond to treatment, correlating with better patient outcomes, and those that were resistant. Importantly, the model also provided insights into its decision-making process by pinpointing the protein complexes driving resistance in cervical cancer. This interpretability feature of the model is crucial not only for its effectiveness but also in establishing reliable AI systems in medical applications.

"Clinicians were previously aware of a few individual mutations that are associated with treatment resistance, but these isolated mutations tended to lack significant predictive value. The reason is that a much larger number of mutations can shape a tumor's treatment response than previously appreciated," said Trey Ideker, PhD, professor in Department of Medicine at UC San Diego of Medicine. "Artificial intelligence bridges that gap in our understanding, enabling us to analyze a complex array of thousands of mutations at once."

"Unraveling an AI model's decision-making process is crucial, sometimes as important as the prediction itself," added Ideker. "Our model's transparency is one of its strengths, first because it builds trust in the model, and second because each of these molecular assemblies we’ve identified becomes a potential new target for chemotherapy. We’re optimistic that our model will have broad applications in not only enhancing current cancer treatment, but also in pioneering new ones."

Related Links:
University of California San Diego


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Increased albuminuria has been found to be associated with a higher risk of all-cause dementia (L Luo et al., J Intern Med (2025). doi.org/10.1111/joim.70022)

Urine Protein Test Can Predict Dementia Risk

Dementia remains one of the most pressing health challenges worldwide, with age as the greatest risk factor. Increasingly, research suggests that diseases in other organs, such as the kidneys, may play... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: Lunit and Agilent Technologies are collaborating to develop AI-powered companion diagnostics. (Photo courtesy of Lunit)

Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics

Biomarker testing plays a critical role in precision oncology, guiding tailored therapies for patients. However, current methods often rely heavily on manual interpretation, which can introduce variability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.